poisar

Stocks · News reference

BioNTech and Bristol Myers Squibb Report Encouraging Phase 2 Data for Pumitamig in Advanced NSCLC

BioNTech SE and Bristol Myers Squibb announced initial data from the global Phase 2 ROSETTA Lung-107 study, showing an objective response rate of 36.7% for the bispecific immunomodulator Pumitamig in combination with docetaxel.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BNTX
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. Biontech Se And Dualitybio

    BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

    BioNTech and DualityBio announced that their Phase 3 DYNASTY-Breast02 trial met its primary endpoint, showing statistically significant but modest improvement in progression-free survival with trastuzumab pamirtecan versus chemotherapy in HR+/HER2-low metastatic breast cancer patients. However, a higher rate of interstitial lung disease was observed, and the companies noted limited potential benefit in the current treatment landscape.

    BNTX
  3. Biontech Se And Dualitybio

    BioNTech und DualityBio geben Topline-Ergebnisse der globalen klinischen Phase-3-Studie DYNASTY-Breast02 für Trastuzumab Pamirtecan bei metastasiertem HR+/HER2-low-Brustkrebs bekannt

    BioNTech and DualityBio announced that their Phase 3 DYNASTY-Breast02 trial met its primary endpoint, showing statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan versus chemotherapy in HR+/HER2-low metastatic breast cancer patients. However, the trial observed a higher rate of interstitial lung disease than previous studies, and the companies concluded the potential patient benefit appears limited given currently available treatment options.

    BNTX